Latest Insider Transactions at Arcus Biosciences, Inc. (RCUS)
This section provides a real-time view of insider transactions for Arcus Biosciences, Inc. (RCUS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Arcus Biosciences, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Arcus Biosciences, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 31
2025
|
Ii Robert C. Goeltz Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
6,552
-8.8%
|
$150,696
$23.38 P/Share
|
|
Dec 30
2025
|
Terry J Rosen Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
2,400
-0.11%
|
-
|
|
Dec 18
2025
|
Alexander Azoy Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
4,343
-18.99%
|
$95,546
$22.25 P/Share
|
|
Dec 17
2025
|
Terry J Rosen Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
25,744
-1.16%
|
$566,368
$22.16 P/Share
|
|
Dec 17
2025
|
Juan C. Jaen President |
SELL
Open market or private sale
|
Direct |
9,983
-2.8%
|
$219,626
$22.16 P/Share
|
|
Dec 17
2025
|
Jennifer Jarrett Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
9,983
-4.92%
|
$219,626
$22.16 P/Share
|
|
Dec 17
2025
|
Ii Robert C. Goeltz Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,960
-7.41%
|
$131,120
$22.16 P/Share
|
|
Dec 17
2025
|
Alexander Azoy Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
2,113
-8.46%
|
$46,486
$22.16 P/Share
|
|
Dec 17
2025
|
Richard Markus Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,494
-6.41%
|
$98,868
$22.16 P/Share
|
|
Dec 17
2025
|
Carolyn C. Tang General Counsel |
SELL
Open market or private sale
|
Direct |
6,810
-5.18%
|
$149,820
$22.16 P/Share
|
|
Dec 16
2025
|
Terry J Rosen Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
28,947
-1.29%
|
$607,887
$21.88 P/Share
|
|
Dec 16
2025
|
Juan C. Jaen President |
SELL
Open market or private sale
|
Direct |
11,225
-3.06%
|
$235,725
$21.88 P/Share
|
|
Dec 16
2025
|
Jennifer Jarrett Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
11,225
-5.24%
|
$235,725
$21.88 P/Share
|
|
Dec 16
2025
|
Ii Robert C. Goeltz Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
6,702
-7.69%
|
$140,742
$21.88 P/Share
|
|
Dec 16
2025
|
Alexander Azoy Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
2,376
-8.68%
|
$49,896
$21.88 P/Share
|
|
Dec 16
2025
|
Richard Markus Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,052
-6.72%
|
$106,092
$21.88 P/Share
|
|
Dec 16
2025
|
Carolyn C. Tang General Counsel |
SELL
Open market or private sale
|
Direct |
7,658
-5.5%
|
$160,818
$21.88 P/Share
|
|
Dec 04
2025
|
Juan C. Jaen President |
SELL
Open market or private sale
|
Indirect |
82,997
-8.0%
|
$1,991,928
$24.71 P/Share
|
|
Nov 26
2025
|
Alexander Azoy Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,900
-6.49%
|
$49,400
$26.0 P/Share
|
|
Nov 26
2025
|
Alexander Azoy Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,900
+6.1%
|
$24,700
$13.33 P/Share
|
|
Nov 26
2025
|
Ii Robert C. Goeltz Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,000
-5.43%
|
$125,000
$25.0 P/Share
|
|
Nov 18
2025
|
Juan C. Jaen President |
SELL
Open market or private sale
|
Indirect |
5,050
-0.48%
|
$95,950
$19.75 P/Share
|
|
Nov 17
2025
|
Juan C. Jaen President |
SELL
Open market or private sale
|
Indirect |
44,950
-2.08%
|
$899,000
$20.47 P/Share
|
|
Nov 07
2025
|
Jennifer Jarrett Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
50,291
-19.01%
|
$905,238
$18.97 P/Share
|
|
Nov 07
2025
|
Jennifer Jarrett Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,291
+15.97%
|
$50,291
$1.23 P/Share
|
|
Oct 30
2025
|
Juan C. Jaen President |
SELL
Open market or private sale
|
Indirect |
4,314
-0.4%
|
$86,280
$20.32 P/Share
|
|
Oct 29
2025
|
Juan C. Jaen President |
SELL
Open market or private sale
|
Indirect |
77,840
-2.26%
|
$1,634,640
$21.35 P/Share
|
|
Oct 28
2025
|
Juan C. Jaen President |
SELL
Open market or private sale
|
Indirect |
19,019
-1.6%
|
$380,380
$20.19 P/Share
|
|
Oct 28
2025
|
Ii Robert C. Goeltz Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,000
-5.15%
|
$100,000
$20.0 P/Share
|
|
Oct 08
2025
|
Jennifer Jarrett Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
37,792
-15.0%
|
$566,880
$15.05 P/Share
|
|
Oct 08
2025
|
Jennifer Jarrett Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
37,792
+13.04%
|
$37,792
$1.23 P/Share
|
|
Oct 06
2025
|
Jennifer Jarrett Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
12,500
-5.51%
|
$175,000
$14.54 P/Share
|
|
Oct 06
2025
|
Jennifer Jarrett Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+5.23%
|
$12,500
$1.23 P/Share
|
|
Sep 29
2025
|
Alexander Azoy Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
2,831
-9.38%
|
$36,803
$13.0 P/Share
|
|
Sep 05
2025
|
Alexander Azoy Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,579
-4.97%
|
$17,369
$11.88 P/Share
|
|
Jun 10
2025
|
Nicole Lambert Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,300
+26.28%
|
-
|
|
Jun 10
2025
|
Yasunori Kaneko Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,300
+28.54%
|
-
|
|
Jun 10
2025
|
David L. Lacey Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,300
+15.79%
|
-
|
|
Jun 10
2025
|
Antoni Ribas Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,300
+23.35%
|
-
|
|
Jun 10
2025
|
Patrick Machado Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,300
+25.63%
|
-
|
|
Jun 10
2025
|
Kathryn E Falberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,300
+16.24%
|
-
|
|
Jun 10
2025
|
Andrew J Perlman Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,300
+23.78%
|
-
|
|
Feb 27
2025
|
Terry J Rosen Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
19,800
+0.77%
|
$198,000
$10.18 P/Share
|
|
Feb 27
2025
|
Yasunori Kaneko Director |
BUY
Open market or private purchase
|
Direct |
20,000
+41.32%
|
$200,000
$10.06 P/Share
|
|
Feb 18
2025
|
Gilead Sciences Inc > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
1,363,636
+4.16%
|
$14,999,996
$11.0 P/Share
|
|
Feb 10
2025
|
Richard Markus Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
75,193
+50.0%
|
-
|
|
Jan 23
2025
|
Alexander Azoy Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,100
+36.16%
|
-
|
|
Jan 23
2025
|
Ii Robert C. Goeltz Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
37,000
+27.58%
|
-
|
|
Jan 23
2025
|
Jennifer Jarrett Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+18.98%
|
-
|
|
Jan 23
2025
|
Terry J Rosen Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
165,000
+6.11%
|
-
|